kramer_edit.qxp 13/11/07 11:50 Page 51
West Nile Virus Eight Years Later—A Mosquito-borne Menace
Sensitive and specific nucleic acid amplification tests were rapidly developed adulticide application, and public education) has been adopted to reduce
for screening the blood supply after transfusion transmission of WNV was mosquito populations. Debate continues over the health and environmental
recognized in 2002.
63
Implementation of the assay in 2003 detected 1.49 effects of pesticides used to control mosquitoes.
42
RNA-positive blood samples per 10,000 donations, at a calculated cost of
$1.7 million per quality-adjusted life year saved.
64
High-throughput assays Four WNV vaccines have been licensed successfully for prevention of
based on Taqman
®
reverse transcription quantitative polymerase chain disease in equines, and trials are under way for human vaccines.
reaction (RT-PCR) were developed in response to intensive testing of Approaches include the use of inactivated vaccines, DNA expression
mosquitoes and dead birds for WNV RNA.
65,66
Rapid diagnostic assays based vector-based and recombinant protein-based immunizations, chimeric
on antigen capture using dipsticks
67
or fluorescence
68
were developed for use virus, and attenuated virus.
42
Treatment using antivirals may be a more
by less sophisticated laboratories than large state-run health departments. reasonable approach taking into account the population most affected
by WN disease and the unpredictable nature of the outbreaks. Potentially
Control effective therapeutics include ribavirin,
69
intravenous immunoglobulin
After eight years of WNV activity in the US, the number of cases is low in the derived from donor plasma with high levels of WNV antibodies,
70
eastern US, while the overall number of cases in the US appears to have humanized monoclonal antibodies directed against the WNV envelope
stabilized (see Table 1). However, a significant increase in the number of cases protein,
71
interferon therapy,
72
and oligomers with complementary
was observed in western Canada in 2007. The virus is now endemic in North sequence to portions of the WNV genome (antisense therapies).
73
America, and changes in activity will most likely be related to weather
conditions. The intensity of transmission of WNV in the US and the epidemic In summary, WNV is a major public health problem, and is likely to remain
proportion of the outbreaks have stimulated the development of effective so for the foreseeable future. The introduction of this virus into the western
methods of limiting viral transmission and preventing and/or treating WN hemisphere in 1999 precipitated intensive research, which has increased our
disease. Efforts have focused on reducing mosquito vector populations and understanding of the ecology, pathogenesis, and epidemiology of this virus
encouraging use of personal protective measures (long sleeves, insect greatly. The event heightened awareness of the consequences of naturally
repellents) to limit exposure to mosquito bites. A multifaceted approach introduced pathogens. It is clear that we will face similar challenges from
(mosquito population monitoring, mosquito source reduction, larvicide and newly introduced zoonotic pathogens in the future. ■
1. Burke DS, Monath TP, Fields Virology, fourth edn, Philadelphia: 72(5):612–15. 50. Malkinson M, Banet C, Curr Top Microbiol Immunol, 2002;267:
Lippincott William & Wilkins, 2001;1043–1126. 26. Berrocal L, Pena J, Gonzalez M, Mattar S, Rev Saude Publica 309–22.
2. Brinton MA, Annu Rev Microbiol, 2002;56:371–402. (Bogota), 2006;8(2):218–28. 51. Bakonyi T, Ivanics E, Erdelyi K, et al., Emerg Infect Dis, 2006;12(4):
3. Rice CM, Fields Virology, third edn, Philadelphia: Lippincott-Raven 27. Bosch I, Herrera F, Navarro JC, et al., Emerg Inf Dis, 2007;13(4):651–3. 618–23.
Publishers, 1996;931–60. 28. Ebel GD, Carricaburu J, Young D, et al., Am J Trop Med Hyg, 52. Kramer LD, Li J, Shi P-Y, Lancet Neurol, 2007;6:171–81.
4. Smithburn KC, Hughes TP, Burke AW, Paul JH, Am J Trop Med Hyg, 2004;71(4): 493–500. 53. Tonry JH, Xiao SY, Siirin M, et al., Am J Trop Med Hyg, 2005;72(3):
1940;20:471–3. 29. Beasley DW, Davis CT, Guzman H, et al., Virology,2003;309(2): 320–24.
5. Zeller HG, Schuffenecker I, Eur J Clin Microbiol Infect Dis, 190–95. 54. Austgen LE, Bowen RA, Bunning ML, et al., Emerg Infect Dis,
2004;23(3):147–56. 30. Davis CT, Beasley DW, Guzman H, et al., Emerg Infect Dis, 2004; 10(1):82–6.
6. Berthet FX, Zeller HG, Drouet MT, et al., J Gen Virol, 1997;78 2003;9(11): 1423–9. 55. Petersen LR, Hayes EB, N Engl J Med, 2004;351(22):2257–9.
(Pt 9):2293–7. 31. Davis CT, Ebel GD, Lanciotti RS, et al., Virology, 2005;342(2):252–65. 56. Yamshchikov G, Borisevich V, Kwok CW, et al., Vaccine, 2005;
7. Bakonyi T, Hubalek Z, Rudolf I, Nowotny N, Emerg Infect Dis, 32. Marra PP, Griffing SM, McLean RG, Emerg Infect Dis, 2003;9(7):898–9. 23(39):4785–92.
2005;11(2):225–31. 33. Beasley DW, Whiteman MC, Zhang S, et al., J Virol,2005;79(13): 57. Buckley A, Dawson A, Gould EA, Virol J, 2006;3:71–6.
8. Lvov DK, Butenko AM, Gromashevsky VL, et al., Arch Virol, 8339–47. 58. Fonseca DM, Keyghobadi N, Malcolm CA, et al., Science, 2004;
2004;(Suppl. 18):85–96. 34. Komar N, Langevin S, Hinten S, et al., Emerg Infect Dis, 2003;9(3): 303(5663):1535–8.
9. Bondre VP, Jadi RS, Mishra AC, et al., Gen Virol, 2007;88(Pt 3): 311–22. 59. Gould EA, Lamballerie X, Zanotto PM, Holmes EC, Adv Virus Res,
875–84. 35. Bernard KA, Dupuis AP II, Ebel GD, et al., Proceedings of the 20th 2003;59:277–314.
10. Hammam HM, Clarke DH, Price WH, Am J Epidemiol, 1965;82:40. Annual Meeting of the American Society for Virology, 78, July 21, 2001. 60. Hoekstra C, Prog Transplant, 2005;15(4):397–400.
11. Lanciotti RS, Ebel GD, Deubel V, et al., Virology, 2002;298(1):96–105. 36. Hochachka WM, Dhondt AA, McKowan KA, Kramer LD, EcoHealth, 61. Sejvar JJ, Clin Infect Dis, 2007;44(12):1617–24.
12. Jia XY, Briese T, Jordan I, et al., Lancet, 1999;354:1971–2. 2004;1(1):60–68. 62. Hayes EB, Sejvar JJ, Zaki SR, et al., Emerg Infect Dis, 2005; 11(8):
13. Samuel MA, Diamond MS, J Virol, 2006;80(19):9349–60. 37. Brault AC, Huang CY, Langevin SA, et al., Nat Genet, 2007;39(9): 1174–9.
14. Hayes CG, Ann NY Acad Sci, 2001;951:25–37. 1162–6. 63. Busch MP, Caglioti S, Robertson EF, et al., N Engl J Med, 2005;
15. Marfin AA, Gubler DJ, Clin Infect Dis, 2001;33(10):1713–19. 38. Brault AC, Langevin SA, Bowen RA, et al., Emerg Infect Dis, 2004; 353(5):460–67.
16. Malkinson M, Banet C, Weisman Y, et al., Emerg Infect Dis, 10(12):2161–8. 64. Mushahwar IK, J Med Virol, 2007;79(8):1229–37.
2002;8(4):392–7. 39. Langevin SA, Brault AC, Panella NA, et al., Am J Trop Med Hyg, 65. Shi P-Y, Kauffman EB, Ren P, et al., J Clin Microbiol, 2001;
17. Dauphin G, Zientara S, Zeller H, Murgue B, Comp Immunol 2005; 72(1):99–102. 39(4):1264–71.
Microbiol Infect Dis, 2004;27(5):343–55. 40. Root JJ, Oesterle PT, Nemeth NM, et al., Am J Trop Med Hyg, 66. Kauffman EB, Jones SA, Dupuis AP, et al., J Clin Microbiol, 2003;
18. MacKenzie JS, Gubler DJ, Petersen LR, Nat Med, 2004;10 (Suppl. 12): 2006; 75(4):697–701. 41(8):3661–7.
S98–109. 41. Kramer LD, Styer LM, Ebel GD, Annu Rev Entomol, 2007; Epub 67. Stone WB, Okoniewski JC, Therrien JE, et al., Emerg Infect Dis,
19. Lanciotti RS, Roehrig JT, Deubel V, et al., Science, 1999;286(5448): ahead of print. 2004; 10(12):2175–81.
2333–7. 42. Kramer LD, Ebel GD, Adv Virus Res, 2003;60:187–232. 68. Stone WB, Therrien JE, Benson R, et al., Emerg Infect Dis, 2005;11:
20. Ebel GD, Dupuis AP II, Ngo KA, et al., Emerg Infect Dis, 2001;7(4): 43. Kilpatrick AM, Kramer LD, Jones MJ, et al., PLoS Biol, 2006;4(4):e82. 1770–73.
650–53. 44. Edman JD, Taylor DJ, Science, 1968;161(3836):67–8. 69. Chowers MY, Lang R, Nassar F, et al., Emerg Infect Dis, 2001;7:675–8.
21. Bernard KA, Maffei JG, Jones SA, et al., Emerg Infect Dis, 45. Nelson RL, Tempelis CH, Reeves WC, Milby MM, Am J Trop Med 70. Shimoni Z, Niven MJ, Pitlick S, Bulvik S, Emerg Infect Dis,
2001;7(4): 679–85. Hyg, 1976;25(4):644–54. 2001;7(4): 759.
22. Kramer LD, Bernard KA, Curr Opin Infect Dis, 2001;14:519–25. 46. Niebylski ML, Meek CL, J Am Mosq Control Assoc, 1992;8(2):173–7. 71. Oliphant T, Engle M, Nybakken GE, et al., Nat Med, 2005;11(6):
23. Dupuis AP, Marra PP, Kramer LD, Emerg Infect Dis, 2003;9(7):860–63. 47. Spielman A, Ann N Y Acad Sci, 2001;951:220–34. 522–30.
24. Blitvich BJ, Fernandez-Salas I, Contreras-Cordero JF, et al., Emerg 48. Kilpatrick AM, Moudy R, Meola M, Kramer LD, Am J Trop Med Hyg, 72. Lewis M, Amsden JR, Pharmacotherapy, 2007;27(3):455–8.
Infect Dis, 2003;9(7):853–6. 2007; in press. 73. Deas TS, Binduga-Gajewska I, Tilgner M, et al., J Virol, 2005;79(8):
25. Cruz L, Cardenas VM, Abarca M, et al., Am J Trop Med Hyg, 2005; 49. Tesh RB, Siirin M, Guzman H, et al., J Infect Dis, 2005;192(2):287–95. 4599–4609.
US INFECTIOUS DISEASE 2007 51